2023 Q1 Form 10-K Financial Statement

#000106299323007846 Filed on March 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $13.08M $10.91M $76.34M
YoY Change -46.02% -52.93% 5.33%
Cost Of Revenue $7.307M $7.185M $45.20M
YoY Change -49.96% -46.8% 10.17%
Gross Profit $5.773M $3.725M $31.13M
YoY Change -40.04% -61.48% -1.0%
Gross Profit Margin 44.14% 34.14% 40.78%
Selling, General & Admin $3.534M $4.643M $15.08M
YoY Change 8.05% 17.12% 23.99%
% of Gross Profit 61.22% 124.64% 48.43%
Research & Development $585.0K $663.9K $2.180M
YoY Change 9.61% 30.77% 19.33%
% of Gross Profit 10.13% 17.82% 7.0%
Depreciation & Amortization $279.8K $268.6K $1.098M
YoY Change 1.04% -4.34% 7.11%
% of Gross Profit 4.85% 7.21% 3.53%
Operating Expenses $4.399M $5.536M $18.36M
YoY Change 9.9% 17.49% 23.77%
Operating Profit $1.387M -$1.810M $13.02M
YoY Change -75.34% -136.5% -21.66%
Interest Expense -$20.92K -$19.14K -$13.55K
YoY Change -439.61% 1159.21% 8368.75%
% of Operating Profit -1.51% -0.1%
Other Income/Expense, Net -$20.92K -$13.55K
YoY Change -439.84% 8212.88%
Pretax Income $1.366M -$1.830M $13.00M
YoY Change -75.74% -136.9% -21.74%
Income Tax $343.0K -$752.2K $3.043M
% Of Pretax Income 25.11% 23.4%
Net Earnings $1.023M -$1.077M $9.960M
YoY Change -75.77% -128.22% -20.79%
Net Earnings / Revenue 7.82% -9.87% 13.05%
Basic Earnings Per Share $0.17 $1.71
Diluted Earnings Per Share $0.16 -$0.18 $1.62
COMMON SHARES
Basic Shares Outstanding 5.971M shares 5.827M shares 5.821M shares
Diluted Shares Outstanding 6.280M shares 6.137M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.37M $7.103M $7.103M
YoY Change 164.24% 39.8% 39.8%
Cash & Equivalents $11.37M $7.103M $7.103M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $4.551M $4.942M $4.942M
YoY Change -16.39% -14.63% -14.63%
Inventory $19.83M $22.81M $22.81M
Prepaid Expenses
Receivables $9.529M $12.84M $12.84M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $45.28M $47.69M $47.69M
YoY Change -4.49% 6.9% 6.9%
LONG-TERM ASSETS
Property, Plant & Equipment $3.151M $3.104M $4.197M
YoY Change -28.97% -0.76% -7.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.30K $40.80K $40.80K
YoY Change -18.99% 22.38% 22.38%
Total Long-Term Assets $4.210M $4.237M $4.237M
YoY Change -6.15% -6.97% -6.97%
TOTAL ASSETS
Total Short-Term Assets $45.28M $47.69M $47.69M
Total Long-Term Assets $4.210M $4.237M $4.237M
Total Assets $49.49M $51.93M $51.93M
YoY Change -4.63% 5.61% 5.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.602M $6.011M $6.011M
YoY Change -68.43% -58.88% -58.88%
Accrued Expenses $273.0K $680.7K $680.7K
YoY Change -2.21% 113.65% 113.65%
Deferred Revenue
YoY Change
Short-Term Debt $645.8K $1.030M $1.030M
YoY Change -2.32% 5.66% 5.66%
Long-Term Debt Due $109.4K $108.4K $108.4K
YoY Change 24.12% 30.18% 30.18%
Total Short-Term Liabilities $8.118M $11.21M $11.21M
YoY Change -51.05% -40.14% -40.14%
LONG-TERM LIABILITIES
Long-Term Debt $115.7K $142.0K $142.0K
YoY Change -31.92% -24.98% -24.98%
Other Long-Term Liabilities $745.6K $811.4K $811.4K
YoY Change -44.72% -41.82% -41.82%
Total Long-Term Liabilities $861.4K $953.4K $953.4K
YoY Change -43.29% -39.8% -39.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.118M $11.21M $11.21M
Total Long-Term Liabilities $861.4K $953.4K $953.4K
Total Liabilities $9.045M $12.23M $12.23M
YoY Change -50.66% -40.46% -40.46%
SHAREHOLDERS EQUITY
Retained Earnings $31.02M $30.00M
YoY Change 49.71%
Common Stock $130.3K $130.3K
YoY Change 0.02% 0.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.44M $39.69M $39.69M
YoY Change
Total Liabilities & Shareholders Equity $49.49M $51.93M $51.93M
YoY Change -4.63% 5.61% 5.61%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $1.023M -$1.077M $9.960M
YoY Change -75.77% -128.22% -20.79%
Depreciation, Depletion And Amortization $279.8K $268.6K $1.098M
YoY Change 1.04% -4.34% 7.11%
Cash From Operating Activities $5.280M $1.338M $3.087M
YoY Change -868.84% -18.25% 10.95%
INVESTING ACTIVITIES
Capital Expenditures $368.5K $279.0K $1.144M
YoY Change -241.24% -213.11% -200.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $58.27K $101.7K
YoY Change -100.0% 2872.96% 5090.31%
Cash From Investing Activities -$368.5K -$220.7K -$1.042M
YoY Change 63.73% -9.8% -8.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $255.8K
YoY Change 883.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$409.7K 923.2K $288.8K
YoY Change 464.65% -18.37% -51.54%
NET CHANGE
Cash From Operating Activities $5.280M 1.338M $3.087M
Cash From Investing Activities -$368.5K -220.7K -$1.042M
Cash From Financing Activities -$409.7K 923.2K $288.8K
Net Change In Cash $4.270M 2.041M $2.081M
YoY Change -533.78% -19.12% -7.16%
FREE CASH FLOW
Cash From Operating Activities $5.280M $1.338M $3.087M
Capital Expenditures $368.5K $279.0K $1.144M
Free Cash Flow $4.911M $1.059M $1.943M
YoY Change -1253.39% -43.76% -50.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
0 usd
CY2021Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
58262 usd
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
0 usd
CY2021Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
320000 usd
CY2022 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
58075 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
291584 usd
CY2022Q4 us-gaap Long Term Debt Maturing In Years Two And Three
LongTermDebtMaturingInYearsTwoAndThree
3596 usd
CY2022 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
80000 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2022 dei Auditor Name
AuditorName
Fitzgerald & Co, CPAs, P.C.
CY2022 dei Auditor Location
AuditorLocation
Vienna, Virginia
CY2022 dei Auditor Firm
AuditorFirmId
58
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
82530 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
255800 usd
CY2021 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
272519 usd
CY2022 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
55171 usd
CY2021 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
297424 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2080509 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-left:72pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Use of Estimates - </strong>The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></span></p> </div>
CY2022 leat Deferred Asset Allowance
DeferredAssetAllowance
105071 usd
CY2022 us-gaap Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
1 pure
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
743621 usd
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
628000 shares
CY2021 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
120000 shares
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
508000 shares
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-left:72pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Concentration of Credit Risk - </strong>The Company maintains cash and cash equivalent balances at several financial institutions that are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. As of December 31, 2022, and 2021, the Company's uninsured bank balances totaled $6,813,511 and $4,751,602, respectively. The Company has not experienced any significant losses on its cash and cash equivalents. </span></span><span><span>The Company's trade receivables are derived from sales to distributors and dealers. The Company has adopted credit policies and standards intended to accommodate industry growth and inherent risk. Management believes that credit risks are moderated by the diversity of the Company's end customers and geographic sales areas. The Company performs ongoing credit evaluations of its customers' financial condition and requires collateral as deemed necessary. The Company maintains allowances for potential credit losses as needed. The Company has derived, and believes that it will continue</span></span></span></span></p> <div/> <p style="margin-left:72pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Concentration of Credit Risk (continued) - </strong>to derive, a significant portion of its revenue from a limited number of customers. For the years ended December 31, 2022 and 2021, the Company's U.S. revenue was concentrated in one customer that accounted for approximately 9% and 10%, respectively, of annual U.S. revenue. As of December 31, 2022, and 2021, $45,030, or 0.3% and $254,477, or 2% of the Company's accounts receivable, respectively, were due from this customer. For the years ended December 31, 2022 and 2021, the Company's international revenue was concentrated in one customer that accounted for approximately 12% and 10%, respectively, of annual international revenue. As of December 31, 2022, and 2021, $1,812,924, or 11%, and $1,273,532, or 10% of the Company's accounts receivable, respectively, were due from this international customer. The Company generates revenue both in the United States and internationally. For the years ended December 31, 2022 and 2021, annual revenues associated with international customers were $59,020,266 and $52,337,504, or 77% and 72% of total revenue, respectively.</span></span></p> </div>
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
25455 usd

Files In Submission

Name View Source Status
0001062993-23-007846-index-headers.html Edgar Link pending
0001062993-23-007846-index.html Edgar Link pending
0001062993-23-007846.txt Edgar Link pending
0001062993-23-007846-xbrl.zip Edgar Link pending
exhibit10-5.htm Edgar Link pending
exhibit10-5x10x1.jpg Edgar Link pending
exhibit10-5x11x1.jpg Edgar Link pending
exhibit10-5x12x1.jpg Edgar Link pending
exhibit10-5x13x1.jpg Edgar Link pending
exhibit10-5x14x1.jpg Edgar Link pending
exhibit10-5x15x1.jpg Edgar Link pending
exhibit10-5x16x1.jpg Edgar Link pending
exhibit10-5x17x1.jpg Edgar Link pending
exhibit10-5x18x1.jpg Edgar Link pending
exhibit10-5x19x1.jpg Edgar Link pending
exhibit10-5x1x1.jpg Edgar Link pending
exhibit10-5x20x1.jpg Edgar Link pending
exhibit10-5x2x1.jpg Edgar Link pending
exhibit10-5x3x1.jpg Edgar Link pending
exhibit10-5x4x1.jpg Edgar Link pending
exhibit10-5x5x1.jpg Edgar Link pending
exhibit10-5x6x1.jpg Edgar Link pending
exhibit10-5x7x1.jpg Edgar Link pending
exhibit10-5x8x1.jpg Edgar Link pending
exhibit10-5x9x1.jpg Edgar Link pending
exhibit10-6.htm Edgar Link pending
exhibit10-6x10x1.jpg Edgar Link pending
exhibit10-6x11x1.jpg Edgar Link pending
exhibit10-6x12x1.jpg Edgar Link pending
exhibit10-6x13x1.jpg Edgar Link pending
exhibit10-6x14x1.jpg Edgar Link pending
exhibit10-6x15x1.jpg Edgar Link pending
exhibit10-6x1x1.jpg Edgar Link pending
exhibit10-6x2x1.jpg Edgar Link pending
exhibit10-6x3x1.jpg Edgar Link pending
exhibit10-6x4x1.jpg Edgar Link pending
exhibit10-6x5x1.jpg Edgar Link pending
exhibit10-6x6x1.jpg Edgar Link pending
exhibit10-6x7x1.jpg Edgar Link pending
exhibit10-6x8x1.jpg Edgar Link pending
exhibit10-6x9x1.jpg Edgar Link pending
exhibit10-8.htm Edgar Link pending
exhibit10-8x001.jpg Edgar Link pending
exhibit10-8x002.jpg Edgar Link pending
exhibit10-8x003.jpg Edgar Link pending
exhibit10-8x10x1.jpg Edgar Link pending
exhibit10-8x11x1.jpg Edgar Link pending
exhibit10-8x12x1.jpg Edgar Link pending
exhibit10-8x13x1.jpg Edgar Link pending
exhibit10-8x14x1.jpg Edgar Link pending
exhibit10-8x15x1.jpg Edgar Link pending
exhibit10-8x16x1.jpg Edgar Link pending
exhibit10-8x17x1.jpg Edgar Link pending
exhibit10-8x1x1.jpg Edgar Link pending
exhibit10-8x2x1.jpg Edgar Link pending
exhibit10-8x3x1.jpg Edgar Link pending
exhibit10-8x4x1.jpg Edgar Link pending
exhibit10-8x5x1.jpg Edgar Link pending
exhibit10-8x6x1.jpg Edgar Link pending
exhibit10-8x7x1.jpg Edgar Link pending
exhibit10-8x8x1.jpg Edgar Link pending
exhibit10-8x9x1.jpg Edgar Link pending
exhibit21.htm Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
exhibit4-26.htm Edgar Link pending
exhibit4-26xu003.jpg Edgar Link pending
exhibit4-26xu004.jpg Edgar Link pending
exhibit4-26xu005.jpg Edgar Link pending
exhibit4-27.htm Edgar Link pending
exhibit4-27x10x1.jpg Edgar Link pending
exhibit4-27x1x1.jpg Edgar Link pending
exhibit4-27x2x1.jpg Edgar Link pending
exhibit4-27x3x1.jpg Edgar Link pending
exhibit4-27x4x1.jpg Edgar Link pending
exhibit4-27x5x1.jpg Edgar Link pending
exhibit4-27x6x1.jpg Edgar Link pending
exhibit4-27x7x1.jpg Edgar Link pending
exhibit4-27x8x1.jpg Edgar Link pending
exhibit4-27x9x1.jpg Edgar Link pending
exhibit4-28.htm Edgar Link pending
exhibit4-28x10x1.jpg Edgar Link pending
exhibit4-28x1x1.jpg Edgar Link pending
exhibit4-28x2x1.jpg Edgar Link pending
exhibit4-28x3x1.jpg Edgar Link pending
exhibit4-28x4x1.jpg Edgar Link pending
exhibit4-28x5x1.jpg Edgar Link pending
exhibit4-28x6x1.jpg Edgar Link pending
exhibit4-28x7x1.jpg Edgar Link pending
exhibit4-28x8x1.jpg Edgar Link pending
exhibit4-28x9x1.jpg Edgar Link pending
exhibit4-29.htm Edgar Link pending
exhibit4-29x1x1.jpg Edgar Link pending
exhibit4-29x2x1.jpg Edgar Link pending
exhibit4-29x3x1.jpg Edgar Link pending
exhibit4-29x4x1.jpg Edgar Link pending
exhibit4-29x5x1.jpg Edgar Link pending
exhibit4-29x6x1.jpg Edgar Link pending
exhibit4-29x7x1.jpg Edgar Link pending
exhibit4-29x8x1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
form10kxz001.jpg Edgar Link pending
form10kxz002.jpg Edgar Link pending
form10kxz003.jpg Edgar Link pending
leat-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
leat-20221231_cal.xml Edgar Link unprocessable
leat-20221231_def.xml Edgar Link unprocessable
leat-20221231_lab.xml Edgar Link unprocessable
leat-20221231_pre.xml Edgar Link unprocessable
form10k_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable